Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 1(4)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00314366Phase 1Completed

Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br)

Role: collaborator

NCT00692926Phase 1Completed

Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells

Role: collaborator

NCT01003912Phase 1Withdrawn

Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases

Role: collaborator

NCT01774097Phase 2Completed

Patients With Intermittent Claudication Injected With ALDH Bright Cells

Role: collaborator

NCT00654433Phase 3Terminated

ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases

Role: lead

NCT01273337Phase 2Unknown

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

Role: lead

NCT00392509Phase 1Completed

ALD-301 for Critical Limb Ischemia, Randomized Trial

Role: lead

All 7 trials loaded